Background. Treatment options of recurrent malignant gliomas are very limited and with a poor survival benefit. The results from phase II trials suggest that the combination of bevacizumab and irinotecan is beneficial. https://www.maximilianopellegrini.com/product-category/daglig-hudpleje/